1. Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: Current research and future perspectives.
- Author
-
Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S, Neves A, Passarinha LA, and Tomaz CT
- Subjects
- Animals, Biomarkers, Humans, Hypoxia, Mice, Neovascularization, Pathologic complications, Prognosis, Retinal Diseases therapy, Vascular Diseases therapy, Vitreous Body chemistry, Placenta Growth Factor metabolism, Retinal Diseases pathology, Vascular Diseases pathology, Vascular Endothelial Growth Factors metabolism
- Abstract
Vision loss due to disease or degeneration of the eye (retina, choroid, retinal veins, or macula) is a leading cause of blindness worldwide. In most cases, vision-threatening ocular diseases are accompanied by abnormal changes in the vasculature of the eye, especially the retina, and these conditions are collectively referred to as retinal vasculopathies. Impaired blood supply or hypoxia stimulates angiogenesis in the vascular and non-vascular sections of the eye, which results in neovascularization, leading to conditions such as diabetic retinopathy or age-related macular degeneration. Studies show that vascular endothelial growth factors: VEGF-A, VEGF-B, and placental growth factor (PlGF) are elevated in these diseases, and hence, these factors could be used as markers for disease prognosis and therapy. In this review, we discuss the function of these growth factors in normal development and disease, with focus on ocular disorders and emphasize the importance of accurately determining their levels in the vitreous and serum of patients for correct diagnosis and therapy., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF